{"doi":"10.3390/md18030167","title":"Antimalarial Peptide and Polyketide Natural Products from the Fijian Marine Cyanobacterium Moorea producens","abstract":"A new cyclic peptide, kakeromamide B (1), and previously described cytotoxic cyanobacterial natural products ulongamide A (2), lyngbyabellin A (3), 18E-lyngbyaloside C (4), and lyngbyaloside (5) were identified from an antimalarial extract of the Fijian marine cyanobacterium Moorea producens. Compounds 1 and 2 exhibited moderate activity against Plasmodium falciparum blood-stages with EC50 values of 0.89 and 0.99 µM, respectively, whereas 3 was more potent with an EC50 value of 0.15 nM. Compounds 1, 4, and 5 displayed moderate liver-stage antimalarial activity against P. berghei liver schizonts with EC50 values of 1.1, 0.71, and 0.45 µM, respectively. The threading-based computational method FINDSITEcomb2.0 predicted the binding of 1 and 2 to potentially druggable proteins of Plasmodium falciparum, prompting formulation of hypotheses about possible mechanisms of action. Kakeromamide B (1) was predicted to bind to several Plasmodium actin-like proteins and a sortilin protein suggesting possible interference with parasite invasion of host cells. When 1 was tested in a mammalian actin polymerization assay, it stimulated actin polymerization in a dose-dependent manner, suggesting that 1 does, in fact, interact with actin.","journal":"Marine Drugs","year":2020,"id":91061,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":46,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9445,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":456397,"name":"Kerstin Gagaring","orcid":"0000-0001-7183-0181","position":1,"is_corresponding":false},{"id":457853,"name":"Jenya Antonova-Koch","orcid":null,"position":2,"is_corresponding":false},{"id":456398,"name":"Hongyi Zhou","orcid":"0000-0001-5074-5180","position":3,"is_corresponding":false},{"id":456399,"name":"Nazia Mojib","orcid":"0000-0003-4924-5538","position":4,"is_corresponding":false},{"id":456400,"name":"Katy Soapi","orcid":"0000-0001-9856-6077","position":5,"is_corresponding":false},{"id":370778,"name":"Jeffrey Skolnick","orcid":"0000-0002-1877-4958","position":6,"is_corresponding":false},{"id":456401,"name":"Case W. McNamara","orcid":"0000-0002-5754-3407","position":7,"is_corresponding":false},{"id":337555,"name":"Julia Kubanek","orcid":"0000-0003-4482-1831","position":8,"is_corresponding":false},{"id":382898,"name":"Anne Marie Sweeney-Jones","orcid":"0000-0003-3419-3149","position":0,"is_corresponding":true}],"reference_count":57,"raw_metadata":null,"created_at":"2026-07-18T22:28:45.409789Z","pmid":"32197482","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}